1st European CAR T Cell Meeting

14th-16th February 2019

Paris, France

Thursday, 14th February

TIME	PLENARY
8:30	
8:45	
9:00	
9:15	
9:30	
9:45	
10:00	
10:15	
10:30	
10:45	
11:00	
11:15	
11:30	**Registration & Welcome lunch**
11:45	
12:00	
12:15	
12:30	**12:30 - 12:45 OPENING CEREMONY** • About EBMT/EHA and their activities ***N. Kröger (EBMT) & P. Sonneveld (EHA)***
12:45	
13:00	**12:45 - 14:15 SCIENTIFIC SESSION** **LATEST CLINICAL DATA**
13:15	
13:30	• CD19 - ALL/Lymphoma | ***C. Roddie (United Kingdom)*** • BCMA - Myeloma | ***A. Garfall (USA)*** • CD123 - AML | ***E. Budde (USA)***
13:45	
14:00	**14:15 - 15:15 SCIENTIFIC SESSION** **When to use CAR-T in…**
14:15	
14:30	• CAR-T cells in acute myeloid leukemia | ***M. Mohty (France)*** • CAR-T cells in lymphoma | ***MJ. Kersten (The Netherlands)*** • CAR-T cells in multiple myeloma | ***H. Einsele (Germany)***
14:45	
15:00	
15:15	**Coffee break**
15:30	
15:45	
16:00	
16:15	**15:45 - 16:30 KEY NOTE LECTURE |** ***S. Riddell (USA)***
16:30	**16:30 – 17:30 SCIENTIFIC SESSION** **CAR-T in pediatrics**
16:45	
17:00	• Titles to be announced ***F. Locatelli (Italy)*** ***A. Baruchel (France)*** ***P. Bader (Germany)***
17:15	
17:30	
17:45	
18:00	**Satellite Symposium**
18:15	
18:30	
18:45	
19:00	
19:15	**Welcome reception & poster session**
19:30	
19:45	

Friday, 15th February

TIME	PLENARY
8:30	
8:45	
9:00	**08:30 - 10:00 SCIENTIFIC SESSION** **Pre-clinical & clinical pipeline - Part 1** ***M. Hudecek (Germany)*** ***K. Straathof (United Kingdom)*** ***G. Dotti (USA)***
9:15	
9:30	• CARs, TRUCKs and beyond: the next generation of CAR T cells | ***H. Abken (Germany)***
9:45	
10:00	**10:00 – 10:45 KEY NOTE LECTURE | *C. June (USA)***
10:15	
10:30	
10:45	**Coffee break**
11:00	
11:15	
11:30	
11:45	**11:15 - 12:15 FLASH TALKS & ABSTRACTS** Speakers to be selected from abstract submissions
12:00	**12:15 - 13:00 KEY NOTE LECTURE |** ***M. Sadelain (USA)***
12:15	
12:30	
12:45	
13:00	**Lunch**
13:15	
13:30	
13:45	**Satellite Symposium 2**
14:00	
14:15	
14:30	**14:30 - 16:00 SCIENTIFIC SESSION** **EMA & industry perspective on CAR-T in EU**
14:45	
15:00	• CAR-T cells - a regulatory view from the EMA Committee for Advanced Therapies | ***M. Schüssler-Lenz (Germany)*** • Novartis | ***A. Bondanza (Italy)*** • Janssen | ***M. Kalos (USA)*** • Celgene | ***S. Frankel (USA)*** • Reimbursement | ***C. Haag (Germany)***
15:15	
15:30	**16:00 – 17:00 SCIENTIFIC SESSION** **Clinical implementation & management**
15:45	
16:00	• Würzburg experience | ***M. Hudecek (Germany)*** • Lille experience | ***I. Yacoub-Agha (France)*** • Milan experience | ***F. Ciceri (Italy)*** • CART19-BE-01 trial | ***J. Delgado (Spain)*** • RWE for CAR T evaluation | ***D. Schulthess (The Netherlands)***
16:15	
16:30	
16:45	
17:00	**Coffee break**
17:15	
17:30	**17:30 - 18:30 SCIENTIFIC SESSION 2** **Pre-clinical & clinical pipeline - Part 1**
17:45	
18:00	• TEGs | ***J. Kuball (Germany)*** • CAR-T Treatment for B-cell ALL: experience from China | ***P. Lu (China)*** • Allogenic CAR T Cells
18:15	
18:30	**Satellite Symposium 3**
18:45	
19:00	
19:15	
19:30	
19:45	

Saturday, 16th February

TIME	GENERAL SESSION 1/3	PARALLEL SESSION 2/3	PARALLEL SESSION 3/3
8:30	**08:30 - 09:45 PARALLEL SESSION 1/3** **General session - Part 1** • CAR-T cells for non immunologists: A simple description of the technology | ***M. Hudecek (Germany)*** • Current status of CAR-T cell development in Europe and elsewhere | ***A. Urbano-Ispizua (Spain)*** • The supply chain for autologous CAR-T cell from a hospital perspective | ***C. Chabannon (France)***	**08:30 - 09:45 PARALLEL SESSION 2/3** **Nurses session - Patient care - Part 1** • What is driving CARs into the spotlight - The science simplified | ***E. Vickers (United Kingdom)*** • A CAR-T for Everything - Overview of current studies and indications • Patient selection and harvesting the CAR | ***M. Vercasson (France)***	**08:30 - 09:45 PARALLEL SESSION 3/3** **Data managers session - Data collection & LTFU - Part 1** • The Cell Therapy Form in the EBMT registry | ***C. Ruiz de Elvira (United Kingdom)*** • The EMA initiative on registries | ***E. McGrath (Spain)*** • Specifics of LTFU for patients treated with gene therapy medicinal products | ***A. van Biezen (The Netherlands)***
8:45			
9:00			
9:15			
9:30			
9:45	**Coffee break**		
10:00			
10:15	**10:15 - 12:00 PARALLEL SESSION 1/3** **General session - Part 2** • Issues with centers selection and qualification | ***T. Pagliuca (United Kingdom)*** • Patient perspectives | ***N. Bolaños (France) & B. Verhoeven (The Netherlands)***	**10:15 - 12:00 PARALLEL SESSION 2/3** **Nurses session - Patient care - Part 2** • Evaluation & Preparation of Pediatric Patients for CAR T-Cell Treatment / Pediatric patient preparation and collection of CAR | ***D. Hutt (Israel)*** • Treatment and nursing assessment post CAR T cells in Ambulatory Care settings / Ambulatory CAR; nursing assessment post IEC | ***D. Comerford (United Kingdom)*** • The EBMT Guidelines for practice / A framework for managing Patient Care, CRS and Neurotoxicity | ***R. Ellard (United Kingdom) & O. Stewart (United Kingdom)***	**10:15 – 12:00 PARALLEL SESSION 3/3** **Data managers session - Data collection & LTFU - Part 2** • PASS Studies and CAR T: Regulatory requirements | ***SR. Terwel (The Netherlands)*** • Example on registration • From Promise to MACRO and minimalized data sets | ***P. Ljungman (Sweden)***
10:30			
10:45			
11:00			
11:15			
11:30			
11:45			
12:00	**Lunch**		
12:15			
12:30			
12:45	**Satellite Symposium 4**		
13:00			
13:15			
13:30	**13:30 - 15:00 PARALLEL SESSION 1/3** **General session - Part 1 - Repeat session** • CAR-T cells for non immunologists: A simple description of the technology | ***M. Hudecek (Germany)*** • Current status of CAR-T cell development in Europe and elsewhere | ***A. Urbano-Ispizua (Spain)*** • The supply chain for autologous CAR-T cell from a hospital perspective | ***C. Chabannon (France)***	**13:30 - 15:00 PARALLEL SESSION 2/3** **Physicians session - Patient care - Part 1** • The Dutch experience for clinical implementation of CAR T cells in children and adults | ***M. Minnema (The Netherlands)*** • Management of CRS and neurotoxicities | ***M. Topp (Germany)*** • A quality system for centers administrating CAR T cells: The JACIE model | ***E. McGrath (Spain)***	**13:30 - 15:00 PARALLEL SESSION 3/3** **Cell collection, cell processing facilities and hospital pharmacies personnel - Mastering the supply chain - Part 1** • Collection of autologous mononuclear cells | ***H. Bönig (Germany)*** • Processing, QC and shipment of collected cells | ***J. Larghero (France)*** • Point-of-care manufacturing
13:45			
14:00			
14:15			
14:30			
14:45			
15:00	**Coffee break**		
15:15			
15:30	**15:30 - 17:00 PARALLEL SESSION 1/3** **General session - Part 2 - Repeat session** • Issues with centers selection and qualification | ***T. Pagliuca (United Kingdom)*** • Patient perspectives | ***N. Bolaños (France) & B. Verhoeven (The Netherlands)***	**15:30 - 17:00 PARALLEL SESSION 2/3** **Physicians session - Patient care - Part 2** • Evaluation of disease response | ***A. Nagler (Israel)*** • Is this the end? The need for consolidation? Bridge to transplantation? CAR-T cells in treatment strategies | ***S. Mielke (Sweden)*** • The EBMT Registry: Fulfilling the needs of multiple stakeholders | ***N. Kröger (Germany)***	**15:30 - 17:00 PARALLEL SESSION 3/3** **Cell collection, cell processing facilities and hospital pharmacies personnel - Mastering the supply chain - Part 2** • Role of the pharmacist in reception, storage and delivery of CAR-T Cells. Transfer to the clinical ward and delivery of the gene therapy medicinal product | ***C. de Haar (The Netherlands)*** • Techniques for thawing cryopreserved CAR-T Cells | ***B. Mfarrej (France)*** • Out-of-Specification CAR-T Cell Products | ***A. Bersenev***
15:45			
16:00			
16:15			
16:30			
16:45			
17:00	**17:00 - 17:15 CLOSING REMARKS**		
17:15			
17:30			
17:45			
18:00			
18:15			
18:30			
18:45			
19:00			
19:15			
19:30			
19:45			